Why the study?
In HFrEF, an obesity paradox exists where higher BMI relates to better survival and weight loss associates with worse outcomes, prompting investigation into whether SGLT2 inhibitor efficacy varies by baseline BMI.
Does dapagliflozin reduce the composite of worsening heart failure or cardiovascular death in HFrEF patients across different baseline BMI categories?
Does dapagliflozin reduce the composite of worsening heart failure or cardiovascular death in HFrEF patients across different baseline BMI categories?
Dapagliflozin provides consistent cardiovascular benefits in patients with HFrEF regardless of baseline BMI, despite the presence of an obesity survival paradox.
Dapagliflozin reduces worsening HF or CV death consistently across BMI in HFrEF; confirms benefit independent of weight.
AIMS: In heart failure with reduced ejection fraction (HFrEF), there is an 'obesity paradox', where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium-glucose co-transporter 2 inhibitor according to baseline BMI in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF). METHODS AND The primary outcome in DAPA-HF was the composite of worsening heart failure or cardiovascular death. Overall, 1348 patients (28.4%) were under/normal-weight, 1722 (36.3%) overweight, 1013 (21.4%) obesity class I and 659 (13.9%) obesity class II/III. The unadjusted hazard ratio (95% confidence interval) for the primary outcome with obesity class 1, the lowest risk group, as reference was: under/normal-weight 1.41 (1.16-1.71), overweight 1.18 (0.97-1.42), obesity class II/III 1.37 (1.10-1.72). Patients with class I obesity were also at lowest risk of death. The effect of dapagliflozin on the primary outcome and other outcomes did not vary by baseline BMI, e.g. hazard ratio for primary outcome: under/normal-weight 0.74 (0.58-0.94), overweight 0.81 (0.65-1.02), obesity class I 0.68 (0.50-0.92), obesity class II/III 0.71 (0.51-1.00) (P-value for interaction = 0.79). The mean decrease in weight at 8 months with dapagliflozin was 0.9 (0.7-1.1) kg (P < 0.001). CONCLUSION: We confirmed an 'obesity survival paradox' in HFrEF. We showed that dapagliflozin was beneficial across the wide range of BMI studied. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03036124.
No takes yet. Share an insight, caveat, or question.
Adamson et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: